Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

First report on prostate displacements immediately before and after treatment relative to the position during VMAT delivery

First report on prostate displacements immediately before and after treatment relative to the... 1206 K. Nakagawa et al. [4] Bonadonna G, Valagussa P. Dose-response effect of adjuvant Acknowledgements chemotherapy in breast cancer. N Engl J Med 1981;/304:/ This study was financially supported by the Finnish 105. [5] Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I. Breast Cancer Group, Kuopio University, and Haematological toxicity: A marker of adjuvant chemotherapy Kuopio University Hospital. I declare that I have efficacy in stage II and III breast cancer. Br J Cancer 1997;/ no conflict of interest. 75:/3015. [6] Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J References Cancer 1999;/80:/17636. [1] Hirvikoski PP, Kumpulainen EJ, Johansson RT. CNF [7] Mayers C, Panzarella T, Tannock IF. Analysis of the combination as adjuvant treatment in breast cancer patients prognostic effects of inclusion in a clinical trial and of is well tolerated. Anti-Cancer Drugs 1997;/8:/3768. myelosuppression on survival after adjuvant chemotherapy [2] Hirvikoski PP, Kumpulainen EJ, Johansson RT. Hepatic for breast carcinoma. Cancer 2001;/91:/224657. toxicity caused by adjuvant CMF/CNF in breast cancer [8] Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindmar H, patients and reversal by tamoxifen. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Oncologica Taylor & Francis

First report on prostate displacements immediately before and after treatment relative to the position during VMAT delivery

Download PDF
3 pages

Loading next page...
 
/lp/taylor-francis/first-report-on-prostate-displacements-immediately-before-and-after-MHEik5qn3U

References (5)

Publisher
Taylor & Francis
Copyright
© 2009 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted
ISSN
1651-226X
eISSN
0284-186X
DOI
10.3109/02841860903101190
pmid
19863231
Publisher site
See Article on Publisher Site

Abstract

1206 K. Nakagawa et al. [4] Bonadonna G, Valagussa P. Dose-response effect of adjuvant Acknowledgements chemotherapy in breast cancer. N Engl J Med 1981;/304:/ This study was financially supported by the Finnish 105. [5] Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I. Breast Cancer Group, Kuopio University, and Haematological toxicity: A marker of adjuvant chemotherapy Kuopio University Hospital. I declare that I have efficacy in stage II and III breast cancer. Br J Cancer 1997;/ no conflict of interest. 75:/3015. [6] Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF. Br J References Cancer 1999;/80:/17636. [1] Hirvikoski PP, Kumpulainen EJ, Johansson RT. CNF [7] Mayers C, Panzarella T, Tannock IF. Analysis of the combination as adjuvant treatment in breast cancer patients prognostic effects of inclusion in a clinical trial and of is well tolerated. Anti-Cancer Drugs 1997;/8:/3768. myelosuppression on survival after adjuvant chemotherapy [2] Hirvikoski PP, Kumpulainen EJ, Johansson RT. Hepatic for breast carcinoma. Cancer 2001;/91:/224657. toxicity caused by adjuvant CMF/CNF in breast cancer [8] Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindmar H, patients and reversal by tamoxifen.

Journal

Acta Oncologica – Taylor & Francis

Published: Jan 1, 2009

There are no references for this article.